Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: High Bleeding Risk Clear all
Active, not recruiting Not applicable Interventional

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

NCT06655207
View directory record Official record
Conditions
Post Partum Haemorrhage, Maternal Care Patterns, High Risk Pregnancy
Interventions
Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding
Device
Lead sponsor
Baymatob Operations Pty Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Denver, Colorado • Baton Rouge, Louisiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.

NCT03218787
View directory record Official record
Conditions
Coronary Artery Lesions
Interventions
XIENCE, DAPT
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
101
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 23, 2026, 5:46 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.

NCT07288489
View directory record Official record
Conditions
Blood Loss, Surgical, Coagulation Disorder
Interventions
Reltodecacog alfa, Usual Pharmacological Care
Drug
Lead sponsor
VarmX B.V.
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
19
States / cities
Chandler, Arizona • Phoenix, Arizona • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Withdrawn Not applicable Interventional

Pre-emptive Hemodynamic Optimization of High Risk Patients Undergoing Elective Major Surgical Procedures

NCT00725972
View directory record Official record
Conditions
Hemorrhage
Interventions
Augment O2 Delivery by hemodynamic protocol, High Risk Surgery
Other · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

NCT00888940
View directory record Official record
Conditions
Bloodloss, Surgical Procedures, Operative
Interventions
Ecallantide, Cyklokapron(R)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 23, 2026, 5:46 PM EDT
Not listed No phase listed Observational

Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery

NCT00653601
View directory record Official record
Conditions
Bleeding, Thrombosis
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
View directory record Official record
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 23, 2026, 5:46 PM EDT
Active, not recruiting Not applicable Interventional

LEADERS FREE II: BioFreedom™ Pivotal Study

NCT02843633
View directory record Official record
Conditions
Acute Coronary Syndrome, High Bleeding Risk
Interventions
BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug
Device · Drug
Lead sponsor
Biosensors Europe SA
Industry
Eligibility
Not listed
Enrollment
1,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
39
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 23, 2026, 5:46 PM EDT
Recruiting Not applicable Interventional

Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding

NCT06188585
View directory record Official record
Conditions
Acute Gastrointestinal Bleeding
Interventions
UI-EWD, Conventional therapy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
22 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
New Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Postpartum Video Education in High Risk Populations

NCT06310720
View directory record Official record
Conditions
Postpartum Hemorrhage, Postpartum Depression, Postpartum Sepsis, Postpartum Preeclampsia, Patient Empowerment, Patient Education, Postpartum Care
Interventions
Video Education
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Active, not recruiting Not applicable Interventional

Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

NCT05568264
View directory record Official record
Conditions
Motor Delay, Premature Birth, Intraventricular Hemorrhage, Hypoxic-Ischemic Encephalopathy, Bronchopulmonary Dysplasia
Interventions
Physical Therapy intervention
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
33 Weeks to 48 Weeks
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Clopidogrel Monotherapy in Patients With High Bleeding Risk

NCT05223335
View directory record Official record
Conditions
Bleeding Complications
Interventions
Clopidogrel, Prasugrel, Tricagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

EVOLVE Short DAPT Study

NCT02605447
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
89
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 23, 2026, 5:46 PM EDT
Recruiting Phase 1 Interventional

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

NCT04323748
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
rituxan
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Year to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Vahalla, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pacifier Activated Device and Mother's Voice in Infants at High-risk for Cerebral Palsy

NCT03230032
View directory record Official record
Conditions
Infant Development, Infant,Premature, Hydrocephalus, Neonatal Encephalopathy, Infarction, PVL, Thrombosis, Intraventricular Hemorrhage
Interventions
pacifier-activated device
Device
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
32 Weeks to 12 Months
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 23, 2026, 5:46 PM EDT
Completed No phase listed Observational

ROTEM® Obstetric Hemorrhage Pilot Study

NCT04409015
View directory record Official record
Conditions
High Risk Postpartum Hemorrhage (PPH)
Interventions
ROTEM - rotation thromboelastometry testing
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 23, 2026, 5:46 PM EDT
Completed No phase listed Observational

Studying Heart Ablation After Left Atrial Closure in High-Bleeding-Risk Atrial Fibrillation Patients

NCT07580937
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Arrhythmia
Interventions
Data collection
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Active, not recruiting Not applicable Interventional

Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients.

NCT03913481
View directory record Official record
Conditions
C.Surgical Procedure; Cardiac
Interventions
Acute normovolemic hemodilution, Standard care
Procedure
Lead sponsor
Università Vita-Salute San Raffaele
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated No phase listed Observational

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke

NCT05421533
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Fullerton, California • Boca Raton, Florida • Homestead, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 23, 2026, 5:46 PM EDT
Not yet recruiting Phase 4 Interventional

Prothrombin Complex Concentrate (PCC)

NCT07881393
View directory record Official record
Conditions
Cardiopulmonary Bypass
Interventions
Four Factor Prothrombin Complex Concentrate, ROTEM (Rotational Thromboelastometry) analyzer (TEM International GmbH)
Drug · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)

NCT03647475
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT
Combination Product
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
East Syracuse, New York • New York, New York • Anderson, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
Drug · Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
75 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery

NCT01728636
View directory record Official record
Conditions
Curvature of Spine
Interventions
Tranexamic Acid
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 23, 2026, 5:46 PM EDT
Completed No phase listed Observational

Urokinase Like Plasminogen Activator Levels in Patients Undergoing Bronchoscopy

NCT00929565
View directory record Official record
Conditions
Hemoptysis
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Oct 23, 2026, 5:46 PM EDT